Oral oncology最新文献

{"title":"Prognostic implications of lymph node yield in pediatric patients with N1b papillary thyroid cancer","authors":"Yizhuo Wei ,&nbsp;Liu Xiao ,&nbsp;Lina Liu ,&nbsp;Lei Shi ,&nbsp;Yu Wang ,&nbsp;Bin Liu","doi":"10.1016/j.oraloncology.2024.106984","DOIUrl":"10.1016/j.oraloncology.2024.106984","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate whether lymph node (LN) yield influences clinical outcomes for pediatric patients with laterocervical lymph node metastasis (N1b) from papillary thyroid cancer (PTC).</p></div><div><h3>Methods</h3><p>Conducted from January 1, 2008, to December 31, 2022, this was a cohort study of pediatric patients (aged ≤ 18 years) with N1b PTC who underwent total thyroidectomy and therapeutic LN dissection in the central and lateral compartments at 3 hospitals in southwest China in 2008–2021, with follow-up until 2022. Patients with distant metastasis were excluded. Univariate and multivariate Cox proportional hazards regression analyses were used to identify factors associated with persistent/recurrent diseases.</p></div><div><h3>Results</h3><p>A total of 102 pediatric patients (median [range] age, 16 [6–18] years) were analyzed: 36 patients (35 %) with T1; 27 patients (26 %), T2; 18 patients (18 %), T3; and 21 patients (21 %), T4. During a median follow-up of 50 months (range, 12–154 months), persistent diseases occurred in 40 (39 %) patients. Receiver operating characteristic analysis identified LN yield cut‐off (&lt;42 LNs) to predict persistent diseases. Multivariate analysis revealed that a less-extensive lymphadenectomy (&lt;42 LNs) was an independent risk factor for persistent diseases (hazard ratio, 2.4; 95 % confidence intervals, 1.09–5.29; P=.029).</p></div><div><h3>Conclusions</h3><p>Our study highlights that a higher LN yield may favorably influence prognosis in pediatric patients with N1b PTC.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142020473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy","authors":"Sulaiman Alsheikh ,&nbsp;Jie Su ,&nbsp;Brian O’Sullivan ,&nbsp;Jolie Ringash ,&nbsp;John N Waldron ,&nbsp;Scott V Bratman ,&nbsp;John Cho ,&nbsp;Enrique Sanz Garcia ,&nbsp;Anna Spreafico ,&nbsp;John de Almeida ,&nbsp;Ezra Hahn ,&nbsp;Andrew Hope ,&nbsp;Ali Hosni ,&nbsp;John Kim ,&nbsp;Andrew McPartlin ,&nbsp;Jillian Tsai ,&nbsp;Tong Li ,&nbsp;Wei Xu ,&nbsp;Eugene Yu ,&nbsp;Shao Hui Huang","doi":"10.1016/j.oraloncology.2024.107007","DOIUrl":"10.1016/j.oraloncology.2024.107007","url":null,"abstract":"<div><h3>Objectives</h3><p>Clinical extranodal extension (cENE) is a cN modifier in TNM-8 for laryngo-hypopharygeal carcinoma (LHC). We hypothesize that image-detected ENE (iENE) can provide additional prognostic value over cENE in LHC.</p></div><div><h3>Methods</h3><p>Baseline CTs/MRIs of cN+ LHC patients treated with definitive (chemo-)radiotherapy between 2010–2019 were re-reviewed by a neuroradiologist using internationally accepted criteria for iENE-positive/negative (iENE+/iENE–). Overall survival (OS) was compared by iENE status. Multivariable analysis (MVA) was performed to confirm the prognostic value of iENE, adjusted for known potential confounders.</p></div><div><h3>Results</h3><p>A total of 232 LHC patients were identified, including 154 iENE–/cENE–, 60 iENE+/cENE–, and 18 iENE+/cENE+. A higher proportion of iENE+ (vs iENE–) patients had lymph node (LN) size &gt; 3 cm [53 (67 %) vs 4 (3 %)], &gt;=5 LNs [51 (65 %) vs 33 (21 %)], and retropharyngeal LN [12 (15 %) vs 6 (4 %)] (all p &lt; 0.01). Median follow-up was 4.8 years. iENE+/cENE– and iENE+/cENE+patients had similarly low 5-year OS [28 % (18–44) and 29 % (13–63)] vs iENE–/cENE– [53 % (45–62)] (p &lt; 0.001). On MVA, mortality risk was higher with iENE+vs iENE– [hazard ratio (HR) 2.22 (95 % CI 1.47–3.36)]. The prognostic value of iENE remained with MVA in larynx (n = 124) (HR 2.51 [1.35–4.68], p = 0.004] or hypopharynx (n = 108) (HR 1.87 [1.02–3.43], p = 0.04) patients, separately.</p></div><div><h3>Conclusions</h3><p>Our study confirms the independent prognostic importance of iENE for LHC following definitive (chemo-)radiotherapy beyond TNM-8 cN status that already contains the cENE parameter. Further research is needed to explore whether iENE could replace cENE for future cN classification.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142020474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results of CO2 laser surgery in laryngeal papillomatosis","authors":"Paweł Solarz ,&nbsp;Hanna Mackiewicz–Nartowicz ,&nbsp;Anna Sinkiewicz ,&nbsp;Paweł Burduk","doi":"10.1016/j.oraloncology.2024.107004","DOIUrl":"10.1016/j.oraloncology.2024.107004","url":null,"abstract":"<div><p>Recurrent respiratory papillomatosis is medical condition strictly connected with HPV infection of the epithelium of the upper respiratory track. The main treatment of lesions located in larynx or lower pharynx includes microsurgical excision by using CO2 laser. A thorough preoperative assessment of patients is extremely important, which should not only be based on traditional laryngological examination, but also on endoscopy of the larynx and the use of the NBI (narrow band imaging) technique to assess the vascularization of lesions. In patients with recurrent papillomas, neoadjuvant therapy with antiviral agents or agents that inhibit angiogenesis is also often used. Among our group of 31 patients with laryngeal papillomas, 15 people (48%) required repeated surgical intervention and additional antiviral therapy while 10 (33%) people had to undergo the procedure three or more times due to disease recurrence. In this article we will discuss that laryngeal microsurgery with a CO2 laser is an effective method of treating patients with laryngeal papillomatosis and we will present the possibilities of adjuvant therapy.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1368837524003221/pdfft?md5=3c31a74584be9b7446d2ea0eb570089a&pid=1-s2.0-S1368837524003221-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142006738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer","authors":"Glenn J. Hanna ,&nbsp;Jamie Jabalee ,&nbsp;John N. Lukens ,&nbsp;Lova Sun ,&nbsp;Eleni M. Rettig ,&nbsp;Rocco Ferrandino II ,&nbsp;Marshall R. Posner ,&nbsp;Krzysztof J. Misiukiewicz ,&nbsp;David M. Routman ,&nbsp;Kathryn M. Van Abel ,&nbsp;Catherine Del Vecchio Fitz ,&nbsp;Scott A. Roof","doi":"10.1016/j.oraloncology.2024.107002","DOIUrl":"10.1016/j.oraloncology.2024.107002","url":null,"abstract":"<div><h3>Background</h3><p>Human papillomavirus (HPV) is causally linked to oropharyngeal squamous cell carcinoma (OPSCC). Testing for plasma tumor tissue modified viral (TTMV)-HPV DNA has emerged as a biomarker strategy for post-treatment surveillance to identify recurrent disease. We aimed to understand the prognostic and predictive potential of TTMV-HPV DNA when monitoring patients who had developed recurrent or metastatic (R/M) HPV+OPSCC.</p></div><div><h3>Methods</h3><p>This retrospective observational cohort study included 80 patients from 4 academic centers with R/M HPV+OPSCC if they had ≥ 1 plasma TTMV-HPV DNA test obtained at any point during their R/M disease course. Physician-reported clinical data and treatment history were captured in a centralized database, along with investigator-assessed response to therapy and survival. Descriptive statistics and non-parametric tests of association were employed along with survival analyses (Kaplan-Meier method).</p></div><div><h3>Results</h3><p>Sixteen (20 %) patients had ≥ 5 test results over time. Consecutive TTMV-HPV DNA tests were performed a median of 73 days apart. Median TTMV-HPV DNA scores were higher with an increasing per-patient number of metastatic sites (&lt;2 vs. 2+; p &lt; 0.01). Score changes over time were influenced by R/M treatment modality and became undetectable in 67 % (12/18) of patients who achieved a complete response to R/M therapy. Patients with detectable scores at last follow-up had significantly worse survival compared with those who were undetectable (log-rank test, p &lt; 0.01).</p></div><div><h3>Conclusions</h3><p>TTMV-HPV DNA appears useful as a prognostic tool for monitoring response to therapy in the R/M setting. In the future, TTMV-HPV DNA could be explored as an exploratory clinical trial endpoint in the metastatic setting.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142002391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)","authors":"Lova Sun ,&nbsp;Roger B. Cohen ,&nbsp;A. Dimitrios Colevas","doi":"10.1016/j.oraloncology.2024.106997","DOIUrl":"10.1016/j.oraloncology.2024.106997","url":null,"abstract":"<div><h3>Objectives</h3><p>Pembrolizumab +/− chemotherapy is standard therapy for r/m HNSCC. Despite regulatory approval of platinum/5FU/pembrolizumab, a taxane is often substituted for 5FU for convenience and tolerability. We aimed to characterize nationwide use patterns and compare outcomes between platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab.</p></div><div><h3>Methods</h3><p>Patients in a US nationwide database with r/m HNSCC treated from 2017 to 2022 with pembrolizumab plus platinum chemotherapy were included. Demographic and cancer-specific characteristics were summarized. Overall survival (OS) was estimated using Kaplan-Meier methodology, and compared between groups using log-rank test and multivariable Cox regression. Time on treatment, number of cycles, receipt of second-line therapy, and toxicities were compared between groups.</p></div><div><h3>Results</h3><p>Of 438 patients, 320 (73 %) received 5FU and 118 (27 %) received a taxane. Taxane use became more frequent over time and was higher in academic vs community practices (51 % vs 23 %, p &lt; 0.001). OS did not differ between taxane and 5FU groups (mOS 12.2 vs 13.4 months, p = 0.662). On multivariable Cox regression, HR for death associated with taxane vs 5FU was 0.99 (95 %CI 0.71–1.38). Receipt of 2L therapy was numerically higher for 5FU patients (46 %) compared to taxane patients (35 %, p = 0.071). Grade ≥ 3 anemia was more common in taxane patients (33 % vs 20 %, p = 0.003), whereas grade ≥ 3 lymphopenia and thrombocytopenia were numerically higher in 5FU patients.</p></div><div><h3>Conclusion</h3><p>In patients with r/m HNSCC undergoing chemoimmunotherapy, taxane vs 5FU use varies by practice setting and geographical region. Platinum/taxane/pembrolizumab was associated with similar survival as platinum/5FU/pembrolizumab; these results suggest that chemoimmunotherapy with taxane is a reasonable alternative to 5FU.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142002390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of microbiota in nasopharyngeal cancer: Where do we stand?","authors":"Sumel Ashique ,&nbsp;Mohammad Houshyari ,&nbsp;Anas Islam ,&nbsp;Radheshyam Pal ,&nbsp;Shakira Ghazanfar ,&nbsp;Farzad Taghizadeh-Hesary","doi":"10.1016/j.oraloncology.2024.106982","DOIUrl":"10.1016/j.oraloncology.2024.106982","url":null,"abstract":"<div><p>Nasopharyngeal carcinoma (NPC) is a common head and neck cancer with a poor prognosis. One of the crucial challenges regarding NPC is its pathogenesis. Recent findings highlight the significance of host microbiota in the development of NPC, affected locally by nasopharyngeal microbiota or remotely by oral microbiota. The oral microbiota can migrate to the nasopharyngeal space, thereby impacting the composition of the nasopharyngeal microbiota. Specific bacterial strains have been linked to the development of nasopharyngeal cancer, including <em>Neisseria</em>, <em>Staphylococcus</em>, <em>Leptotrichia</em>, <em>Staphylococcaceae</em>, <em>Granulicatella</em>, <em>Corynebacterium</em>, <em>Fusobacterium</em>, and <em>Prevotella</em>. Several mechanisms have been proposed to elucidate how microbiota dysbiosis contributes to the development of NPC, including triggering tumor-promoting inflammation, reactivating the Epstein-Barr virus (EBV), inducing oxidative stress, weakening the immune system, and worsening tumor hypoxia. In addition, the composition of nasopharyngeal microbiota and the number of tumor-infiltrating microbiota can influence the prognosis and treatment response in patients with NPC. To the best of our knowledge, this is the first review discussing the impacts of the host microbiota on nasopharyngeal cancer pathogenesis, progression, and treatment response.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141993210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma","authors":"Jinling Yuan ,&nbsp;Mengxing Wu ,&nbsp;Lei Qiu ,&nbsp;Weilin Xu ,&nbsp;Yinjiao Fei ,&nbsp;Yuchen Zhu ,&nbsp;Kexin Shi ,&nbsp;Yurong Li ,&nbsp;Jinyan Luo ,&nbsp;Zhou Ding ,&nbsp;Xinchen Sun ,&nbsp;Shu Zhou","doi":"10.1016/j.oraloncology.2024.106980","DOIUrl":"10.1016/j.oraloncology.2024.106980","url":null,"abstract":"<div><h3>Objective</h3><p>The early response to concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) is closely correlated with prognosis. In this study, we aimed to predict early response using a combined model that combines sub-regional radiomics features from multi-sequence MRI with clinically relevant factors.</p></div><div><h3>Methods</h3><p>A total of 104 patients with LA-NPC were randomly divided into training and test cohorts at a ratio of 3:1. Radiomic features were extracted from subregions within the tumor area using the K-means clustering method, and feature selection was performed using LASSO regression. Four models were established: a radiomics model, a clinical model, an Intratumor Heterogeneity (ITH) score-based model and a combined model that integrates the ITH score with clinical factors. The predictive performance of these models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).</p></div><div><h3>Results</h3><p>Among the models, the combined model incorporating the ITH score and clinical factors exhibited the highest predictive performance in the test cohort (AUC=0.838). Additionally, the models based on ITH score showed superior prognostic value in both the training cohort (AUC=0.888) and the test cohort (AUC=0.833).</p></div><div><h3>Conclusion</h3><p>The combined model that integrates the ITH score with clinical factors exhibited superior performance in predicting early response following concurrent chemoradiotherapy in patients with LA-NPC.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1368837524002987/pdfft?md5=70e06afc17a55cbfada834c70235886f&pid=1-s2.0-S1368837524002987-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141991192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study","authors":"Rui Yang ,&nbsp;Ruichen Li ,&nbsp;Xiaoshuang Niu ,&nbsp;Yang Zhao ,&nbsp;Li Yan ,&nbsp;Shu Tian ,&nbsp;Yi Zhu ,&nbsp;JianJian Qiu ,&nbsp;Xiaoshen Wang","doi":"10.1016/j.oraloncology.2024.106981","DOIUrl":"10.1016/j.oraloncology.2024.106981","url":null,"abstract":"<div><h3>Purpose</h3><p>To evaluate the effectiveness and safety of low-dose gemcitabine and metronomic capecitabine in combination with tislelizumab for patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who have previously received other anti-PD-1 therapies.</p></div><div><h3>Methods</h3><p>This retrospective, observational study included patients with RM-NPC who had prior treatment with anti-PD-1 therapy and subsequently received tislelizumab along with low-dose gemcitabine and metronomic capecitabine between March 2019 and August 2023. Progression-free survival (PFS) was estimated using the Kaplan-Meier method.</p></div><div><h3>Results</h3><p>Among 25 eligible patients, 8 (20%) achieved a complete response (CR). The objective response rate (ORR) was 68%, and the disease control rate (DCR) was 80%. The 1-year PFS rate was 78%. All patients experienced treatment-related adverse events, which were all grade 1 or 2.</p></div><div><h3>Conclusion</h3><p>The combination of tislelizumab with low-dose gemcitabine and metronomic capecitabine demonstrated promising antitumor effectiveness in RM-NPC patients who had failed previous anti-PD-1 therapy, with a manageable safety profile.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1368837524002999/pdfft?md5=ecea1eb749389216a7609aa65f30bfc0&pid=1-s2.0-S1368837524002999-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141978771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders","authors":"Nourhan I. Hussein ,&nbsp;Andrea H. Molina ,&nbsp;Gemalene M. Sunga ,&nbsp;Moran Amit ,&nbsp;Yu Leo Lei ,&nbsp;Xiao Zhao ,&nbsp;Jeffrey D. Hartgerink ,&nbsp;Andrew G. Sikora ,&nbsp;Simon Young","doi":"10.1016/j.oraloncology.2024.106986","DOIUrl":"10.1016/j.oraloncology.2024.106986","url":null,"abstract":"<div><p>Immunotherapy has developed into an important modality of modern cancer treatment. Unfortunately, checkpoint inhibitor immunotherapies are currently delivered systemically and require frequent administration, which can result in toxicity and severe, sometimes fatal, adverse events. Localized delivery of immunomodulators for oral cancer and oral potentially malignant disorders offers the promise of maximum therapeutic potential and reduced systemic adverse effects. This review will discuss the limitations of current standard-of-care systemic therapies and highlight research advances in localized, intratumoral delivery platforms for immunotherapy for oral cancer and oral potentially malignant disorders.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delta magnetic resonance imaging radiomics features‑based nomogram predicts long‑term efficacy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma","authors":"Guang-Sen Pan ,&nbsp;Xiao-Ming Sun ,&nbsp;Fang-Fang Kong ,&nbsp;Jia-Zhou Wang,&nbsp;Xia-Yun He,&nbsp;Xue-Guan Lu,&nbsp;Chao-Su Hu,&nbsp;Si-Xue Dong,&nbsp;Hong-Mei Ying","doi":"10.1016/j.oraloncology.2024.106987","DOIUrl":"10.1016/j.oraloncology.2024.106987","url":null,"abstract":"<div><h3>Purpose</h3><p>To establish and validate a delta-radiomics-based model for predicting progression-free survival (PFS) in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) following induction chemotherapy (IC).</p></div><div><h3>Methods and Materials</h3><p>A total of 250 LA-NPC patients (training cohort: n = 145; validation cohort: n = 105) were enrolled. Radiomic features were extracted from MRI scans taken before and after IC, and changes in these features were calculated. Following feature selection, a delta-radiomics signature was constructed using LASSO-Cox regression analysis. A prognostic nomogram incorporating independent clinical indicators and the delta-radiomics signature was developed and assessed for calibration and discrimination. Risk stratification by the nomogram was evaluated using Kaplan-Meier methods.</p></div><div><h3>Results</h3><p>The delta-radiomics signature, consisting of 12 features, was independently associated with prognosis. The nomogram, integrating the delta-radiomics signature and clinical factors demonstrated excellent calibration and discrimination. The model achieved a Harrell’s concordance index (C-index) of 0.848 in the training cohort and 0.820 in the validation cohort. Risk stratification identified two groups with significantly different PFS rates. The three-year PFS for high-risk patients who received concurrent chemoradiotherapy (CCRT) or radiotherapy plus adjuvant chemotherapy (RT+AC) after IC was significantly higher than for those who received RT alone, reaching statistical significance. In contrast, for low-risk patients, the three-year PFS after IC was slightly higher for those who received CCRT or RT+AC compared to those who received RT alone; however, this difference did not reach statistical significance.</p></div><div><h3>Conclusions</h3><p>Our delta MRI-based radiomics model could be useful for predicting PFS and may guide subsequent treatment decisions after IC in LA-NPC.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141964372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}